Previous data suggest that apolipoprotein (apo) CIII may inhibit both triglyceride hydrolysis by lipoprotein lipase (LPL) and apo E-mediated uptake of triglyceride-rich lipoproteins by the liver. We studied apo B metabolism in very low density (VLDL), intermediate density (IDL), and low density lipoproteins (LDL) in two sisters with apo CIII-apo AI deficiency. The subjects had reduced levels of VLDL triglyceride, normal LDL cholesterol, and near absence of high density lipoprotein (HDL) cholesterol. Compartmental analysis of the kinetics of apo B metabolism after injection of 125I-VLDL and 131I-LDL revealed fractional catabolic rates (FCR) for VLDL apo B that were six to seven times faster than normal. Simultaneous injection of [3H]glycerol demonstrated rapid catabolism of VLDL triglyceride. VLDL apo B was rapidly and efficiently converted to IDL and LDL. The FCR for LDL apo B was normal. In vitro experiments indicated that, although sera from the apo CIII-apo-AI deficient patients were able to normally activate purified LPL, increasing volumes of these sera did not result in the progressive inhibition of LPL activity demonstrable with normal sera. Addition of purified apo CIII to the deficient sera resulted in 20-50% reductions in maximal LPL activity compared with levels of activity attained with the same volumes of the native, deficient sera. These in vitro studies, together with the in vivo results, indicate that in normal subjects apo CIII can inhibit the catabolism of triglyceride-rich lipoproteins by lipoprotein lipase.
H N Ginsberg, N A Le, I J Goldberg, J C Gibson, A Rubinstein, P Wang-Iverson, R Norum, W V Brown
Year: | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | Total |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Citations: | 2 | 2 | 7 | 13 | 18 | 34 | 13 | 12 | 13 | 15 | 9 | 13 | 7 | 9 | 14 | 6 | 20 | 5 | 3 | 10 | 7 | 13 | 9 | 7 | 10 | 12 | 8 | 7 | 10 | 7 | 12 | 10 | 2 | 4 | 10 | 3 | 4 | 5 | 365 |
Title and authors | Publication | Year |
---|---|---|
Apolipoprotein B Secretion Assay from Primary Hepatocytes
Wang Y, Li X, Huang R, Chen XW, Wang X |
Bio-protocol | 2024 |
Macromolecular Interactions of Lipoprotein Lipase (LPL).
Wheless A, Gunn KH, Neher SB |
Sub-cellular biochemistry | 2024 |
Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here
Hermel M, Lieberman M, Slipczuk L, Rana JS, Virani SS |
Pharmaceutics | 2023 |
Apolipoprotein-CIII O-Glycosylation, a Link between GALNT2 and Plasma Lipids.
Naber A, Demus D, Slieker R, Nicolardi S, Beulens JWJ, Elders PJM, Lieverse AG, Sijbrands EJG, 't Hart LM, Wuhrer M, van Hoek M |
International journal of molecular sciences | 2023 |
Postprandial metabolism of apolipoproteins B48, B100, C-III and E in in humans heterozygous for APOC3 loss-of-function mutations
Marja-Riitta Taskinen, Elias Björnson, Niina Matikainen, Sanni Söderlund, Joel Rämo, Mari Ainola, Antti Hakkarainen, Carina Sihlbom, Annika Thorsell, Linda Andersson, stefano romeo, Martin Adiels, Samuli Ripatti, Markku Laakso, Chris J Packard, Jan Borén |
JCI Insight | 2022 |
RNA-based therapy in the management of lipid disorders: a review.
Blom DJ, Marais AD, Moodley R, van der Merwe N, van Tonder A, Raal FJ |
Lipids in Health and Disease | 2022 |
Malnourishment affects gene expression along the length of the small intestine
Pinho RM, Garas LC, Huang BC, Weimer BC, Maga EA |
Frontiers in Nutrition | 2022 |
Distribution of seven ApoC-III glycoforms in plasma, VLDL, IDL, LDL and HDL of healthy subjects
M Rodríguez, P Rehues, V Iranzo, J Mora, C Balsells, M Guardiola, J Ribalta |
Journal of Proteomics | 2022 |
Associations between Alcohol Consumption and HDL Subspecies Defined by ApoC3, ApoE and ApoJ: the Cardiovascular Health Study.
Wilkens TL, Sørensen H, Jensen MK, Furtado JD, Dragsted LO, Mukamal KJ |
Current Problems in Cardiology | 2022 |
New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3
Kim JY, Kim NH |
Journal of Lipid and Atherosclerosis | 2022 |
Broadening the scope of dyslipidemia therapy by targeting APOC3 and ANGPTL3
Ginsberg HN, Goldberg IJ |
Arteriosclerosis, thrombosis, and vascular biology | 2022 |
Apolipoprotein CIII Is an Important Piece in the Type-1 Diabetes Jigsaw Puzzle
I Valladolid-Acebes, PO Berggren, L Juntti-Berggren |
International journal of molecular sciences | 2021 |
Fasting, non-fasting and postprandial triglycerides for screening cardiometabolic risk
BH Keirns, CM Sciarrillo, NA Koemel, SR Emerson |
Journal of Nutritional Science | 2021 |
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society
HN Ginsberg, CJ Packard, MJ Chapman, J Borén, CA Aguilar-Salinas, M Averna, BA Ference, D Gaudet, RA Hegele, S Kersten, GF Lewis, AH Lichtenstein, P Moulin, BG Nordestgaard, AT Remaley, B Staels, ES Stroes, MR Taskinen, LS Tokgözoğlu, A Tybjaerg-Hansen, JK Stock, AL Catapano |
European Heart Journal | 2021 |
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
RA Calle, NB Amin, S Carvajal-Gonzalez, TT Ross, A Bergman, S Aggarwal, C Crowley, A Rinaldi, J Mancuso, N Aggarwal, V Somayaji, M Inglot, TA Tuthill, K Kou, M Boucher, G Tesz, R Dullea, KK Bence, AM Kim, JA Pfefferkorn, WP Esler |
Nature Medicine | 2021 |
PCSK9 Activity Is Potentiated Through HDL Binding
SA Burnap, K Sattler, R Pechlaner, E Duregotti, R Lu, K Theofilatos, K Takov, G Heusch, S Tsimikas, C Fernandez-Hernando, SE Berry, WL Hall, M Notdurfter, G Rungger, B Paulweber, J Willeit, S Kiechl, B Levkau, M Mayr |
Circulation research | 2021 |
Exploration of Serum Marker Proteins in Mice Induced by Babesia microti Infection Using a Quantitative Proteomic Approach
X Wang, S Ren, X Yang, A Masoudi, X Xue, M Li, H Li, X Zhang, H Wang, J Liu |
The Protein Journal | 2021 |
Prevention and Treatment of Atherosclerosis: Improving State-of-the-Art Management and Search for Novel Targets
A von Eckardstein, C Binder |
2021 | |
Hypertriglyceridemia Acute Pancreatitis: Animal Experiment Research.
Wang L, Xu T, Wang R, Wang X, Wu D |
Digestive Diseases and Sciences | 2021 |
Elevated Levels of Apolipoprotein CIII Increase the Risk of Postprandial Hypertriglyceridemia
Y Guan, X Hou, P Tian, L Ren, Y Tang, A Song, J Zhao, L Gao, G Song |
Frontiers in Endocrinology | 2021 |
Effects of bariatric surgery on lipid-lipoprotein profile
ME Piché, I Tardif, A Auclair, P Poirier |
Metabolism | 2021 |
Working towards full eradication of lipid-driven cardiovascular risk?
NS Nurmohamed, ES Stroes |
Netherlands Heart Journal | 2021 |
A lipid lover’s guide to novel therapeutics for lipid and cardiovascular risk reduction
R Hritani, A Hussain, A Saeed, A Agarwala |
Future Cardiology | 2021 |
Role of growth hormone in hepatic and intestinal triglyceride-rich lipoprotein metabolism
M Maraninchi, A Calabrese, JP Nogueira, F Castinetti, J Mancini, F Mourre, L Piétri, E Bénamo, F Albarel, I Morange, J Dupont-Roussel, A Nicolay, T Brue, S Béliard, R Valéro |
Journal of Clinical Lipidology | 2021 |
Vaccination in Atherosclerosis
FS Nettersheim, LD Vore, H Winkels |
Cells | 2020 |
Apolipoprotein CIII and Angiopoietin-like Protein 8 are Elevated in Lipodystrophy and Decrease after Metreleptin
M Lightbourne, A Wolska, BS Abel, KI Rother, M Walter, Y Kushchayeva, S Auh, RD Shamburek, AT Remaley, R Muniyappa, RJ Brown |
Journal of the Endocrine Society | 2020 |
Emerging Targets for Cardiovascular Disease Prevention in Diabetes
NO Stitziel, JE Kanter, KE Bornfeldt |
Trends in Molecular Medicine | 2020 |
The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
J Borén, CJ Packard, MR Taskinen |
Frontiers in Endocrinology | 2020 |
The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
JM Wilson, A Nikooienejad, DA Robins, WC Roell, JS Riesmeyer, A Haupt, KL Duffin, MR Taskinen, G Ruotolo |
Diabetes, obesity & metabolism | 2020 |
Apolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits
H Yan, M Niimi, F Matsuhisa, H Zhou, S Kitajima, Y Chen, C Wang, X Yang, J Yao, D Yang, J Zhang, M Murakami, K Nakajima, Y Wang, E Liu, J Liang, YE Chen, J Fan |
Arteriosclerosis, thrombosis, and vascular biology | 2020 |
Association of apolipoprotein C3 with insulin resistance and coronary artery calcium in patients with type 1 diabetes
T Buckner, B Shao, RH Eckel, JW Heinecke, KE Bornfeldt, J Snell-Bergeon |
Journal of Clinical Lipidology | 2020 |
Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia
NS Nurmohamed, GM Thie, ES Stroes |
Expert Review of Cardiovascular Therapy | 2020 |
iTRAQ‑based quantitative proteomics analysis of the potential application of secretoneurin gene therapy for cardiac hypertrophy induced by DL‑isoproterenol hydrochloride in mice.
Chen H, Wu M, Jiang W, Liu X, Zhang J, Yu C |
International journal of molecular medicine | 2020 |
Apolipoprotein B48 metabolism in chylomicrons and very low‐density lipoproteins and its role in triglyceride transport in normo‐ and hypertriglyceridemic human subjects
E Björnson, CJ Packard, M Adiels, L Andersson, N Matikainen, S Söderlund, J Kahri, A Hakkarainen, N Lundbom, J Lundbom, C Sihlbom, A Thorsell, H Zhou, MR Taskinen, J Borén |
Journal of Internal Medicine | 2020 |
Causes and Consequences of Hypertriglyceridemia
CJ Packard, J Boren, MR Taskinen |
Frontiers in Endocrinology | 2020 |
Reduced Reverse Cholesterol Transport Efficacy in Healthy Men with Undesirable Postprandial Triglyceride Response
A Motte, J Gall, JE Salem, E Dasque, M Lebot, E Frisdal, S Galier, EF Villard, E Bouaziz-Amar, JM Lacorte, B Charbit, WL Goff, P Lesnik, M Guerin |
Biomolecules | 2020 |
Integrin β3 Deficiency Results in Hypertriglyceridemia Via Disrupting LPL (Lipoprotein Lipase) Secretion
B Xiao, J Mao, B Sun, W Zhang, Y Wang, P Wang, Z Ruan, , H Li, J Zhou, Y Lu, Q Ding, X Wang, J Liu, J Yan, C Luo, X Shi, R Yang, |
Arteriosclerosis, thrombosis, and vascular biology | 2020 |
Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies—a Clinical Perspective
X Jia, J Liu, A Mehta, CM Ballantyne, SS Virani |
Cardiovascular Drugs and Therapy | 2020 |
Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study
JL Katzmann, CM Werner, T Stojakovic, W März, H Scharnagl, U Laufs |
Lipids in Health and Disease | 2020 |
Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study
M Kaltoft, A Langsted, BG Nordestgaard |
European Heart Journal | 2020 |
Oligonucléotide antisens de l’apolipoprotéine C-III : nouveau traitement de certaines hypertriglycéridémies sévères
R Valéro |
Médecine des Maladies Métaboliques | 2020 |
Dyslipidemia is the hallmark of the metabolic syndrome in postmenopausal women
AA Osman, AM Fadlalla |
2020 | |
Is APOC3 the driver of cardiovascular disease in people with type I diabetes mellitus?
Henry Ginsberg, Gissette Reyes-Soffer |
Journal of Clinical Investigation | 2019 |
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv |
2019 | |
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv |
2019 | |
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv |
2019 | |
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv |
2019 | |
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv |
2019 | |
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv |
2019 | |
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv |
2019 | |
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv |
2019 | |
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv |
2019 | |
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv |
2019 | |
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv |
2019 | |
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv |
2019 | |
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv |
2019 | |
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv |
2019 | |
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv |
2019 | |
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv |
2019 | |
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv |
2019 | |
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv |
2019 | |
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv |
2019 | |
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv |
2019 | |
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv |
2019 | |
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv |
2019 | |
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv |
2019 | |
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv |
2019 | |
Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism
G Reyes-Soffer, C Sztalryd, RB Horenstein, S Holleran, A Matveyenko, T Thomas, R Nandakumar, C Ngai, W Karmally, HN Ginsberg, R Ramakrishnan, TI Pollin |
Arteriosclerosis, thrombosis, and vascular biology | 2019 |
ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance
B Ramms, S Patel, C Nora, AR Pessentheiner, MW Chang, CR Green, GJ Golden, P Secrest, RM Krauss, CM Metallo, C Benner, VJ Alexander, JL Witztum, S Tsimikas, JD Esko, PL Gordts |
Journal of lipid research | 2019 |
ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors
NC Kegulian, B Ramms, S Horton, O Trenchevska, D Nedelkov, MJ Graham, RG Lee, JD Esko, HN Yassine, PL Gordts |
Arteriosclerosis, thrombosis, and vascular biology | 2019 |
Life is complicated: so is apoCIII
G Reyes-Soffer, HN Ginsberg |
Journal of lipid research | 2019 |
Role of apolipoprotein C‐III overproduction in diabetic dyslipidaemia
M Adiels, MR Taskinen, E Björnson, L Andersson, N Matikainen, S Söderlund, J Kahri, A Hakkarainen, N Lundbom, C Sihlbom, A Thorsell, H Zhou, KH Pietiläinen, C Packard, J Borén |
Diabetes, obesity & metabolism | 2019 |
The Future of Lipid-lowering Therapy
Zwol, Rimbert, Kuivenhoven |
Journal of Clinical Medicine | 2019 |
Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects
TD Filippatos, A Liontos, EC Christopoulou, MS Elisaf |
Current vascular pharmacology | 2019 |
Apolipoprotein CIII and diabetes. Is there a link?
E Christopoulou, V Tsimihodimos, T Filippatos, M Elisaf |
Diabetes/Metabolism Research and Reviews | 2019 |
Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination
Yamashita, Arai, Yokote, Araki, Matsushita, Nojima, Suganami, Ishibashi |
International journal of molecular sciences | 2019 |
The heparan sulfate proteoglycan grip on hyperlipidemia and atherosclerosis
PL Gordts, JD Esko |
Matrix biology : journal of the International Society for Matrix Biology | 2018 |
Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial)
D Masuda, T Kobayashi, M Sairyou, H Hanada, T Ohama, M Koseki, M Nishida, N Maeda, S Kihara, T Minami, K Yanagi, Y Sakata, S Yamashita |
Journal of Atherosclerosis and Thrombosis | 2018 |
An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans
A Mardinoglu, H Wu, E Bjornson, C Zhang, A Hakkarainen, SM Räsänen, S Lee, RM Mancina, M Bergentall, KH Pietiläinen, S Söderlund, N Matikainen, M Ståhlman, PO Bergh, M Adiels, BD Piening, M Granér, N Lundbom, KJ Williams, S Romeo, J Nielsen, M Snyder, M Uhlén, G Bergström, R Perkins, HU Marschall, F Bäckhed, MR Taskinen, J Borén |
Cell Metabolism | 2018 |
γ-Secretase Inhibition Lowers Plasma Triglyceride-Rich Lipoproteins by Stabilizing the LDL Receptor
KJ Kim, IJ Goldberg, MJ Graham, M Sundaram, E Bertaggia, SX Lee, L Qiang, RA Haeusler, D Metzger, P Chambon, Z Yao, HN Ginsberg, UB Pajvani |
Cell Metabolism | 2018 |
Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein MetabolismHighlights
DC Chan, GF Watts, R Somaratne, SM Wasserman, R Scott, PH Barrett |
Arteriosclerosis, thrombosis, and vascular biology | 2018 |
Increased inflammation, endoplasmic reticulum stress and oxidative stress in endothelial and macrophage cells exacerbate atherosclerosis in ApoCIII transgenic mice
H Yingchun, M Yahong, W Jiangping, H Xiaokui, Z Xiaohong |
Lipids in Health and Disease | 2018 |
Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study
JC van Capelleveen, SR Lee, R Verbeek, JJ Kastelein, NJ Wareham, ES Stroes, GK Hovingh, KT Khaw, SM Boekholdt, JL Witztum, S Tsimikas |
Journal of Clinical Lipidology | 2018 |
Update on the laboratory investigation of dyslipidemias
I Ramasamy |
Clinica chimica acta; international journal of clinical chemistry | 2018 |
Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D
A Basu, AJ Jenkins, JA Stoner, Y Zhang, RL Klein, MF Lopes-Virella, WT Garvey, DS Schade, J Wood, P Alaupovic, TJ Lyons |
Journal of lipid research | 2018 |
Roundtable discussion: Familial chylomicronemia syndrome: Diagnosis and management
WV Brown, I Goldberg, B Duell, D Gaudet |
Journal of Clinical Lipidology | 2018 |
Pharmacological Management of Dyslipidemia in Atherosclerosis: Limitations, Challenges, and New Therapeutic Opportunities
KE Kypreos, R Bitzur, EA Karavia, E Xepapadaki, G Panayiotakopoulos, C Constantinou |
Angiology | 2018 |
Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study
JC van Capelleveen, SR Lee, R Verbeek, JJ Kastelein, NJ Wareham, ES Stroes, GK Hovingh, KT Khaw, SM Boekholdt, JL Witztum, S Tsimikas |
Journal of Clinical Lipidology | 2018 |
Lipid management in patients with chronic kidney disease
CJ Ferro, PB Mark, M Kanbay, P Sarafidis, GH Heine, P Rossignol, ZA Massy, F Mallamaci, JM Valdivielso, J Malyszko, MC Verhaar, R Ekart, R Vanholder, G London, A Ortiz, C Zoccali |
Nature Reviews Nephrology | 2018 |
A Novel Role for RARα Agonists as Apolipoprotein CIII Inhibitors Identified from High Throughput Screening
SJ Lee, M Mahankali, A Bitar, H Zou, E Chao, H Nguyen, J Gonzalez, D Caballero, M Hull, D Wang, PG Schultz, W Shen |
Scientific Reports | 2017 |
Apolipoprotein C-III Levels and Incident Coronary Artery Disease RiskHighlights: The EPIC-Norfolk Prospective Population Study
JC van Capelleveen, SJ Moens, X Yang, JJ Kastelein, NJ Wareham, AH Zwinderman, ES Stroes, JL Witztum, GK Hovingh, KT Khaw, SM Boekholdt, S Tsimikas |
Arteriosclerosis, thrombosis, and vascular biology | 2017 |
Bile Acids in Gastroenterology
S Tazuma, H Takikawa |
Bile Acids in Gastroenterology | 2017 |
Lipid deposition in kidney diseases: interplay among redox, lipid mediators and renal impairment
H Su, C Wan, CT Lei, CY Zhang, C Ye, H Tang, Y Qiu, C Zhang |
Antioxidants & Redox Signaling | 2017 |
The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation
M Sundaram, KR Curtis, MA Alipour, ND LeBlond, KD Margison, RA Yaworski, RJ Parks, AD McIntyre, RA Hegele, MD Fullerton, Z Yao |
Journal of lipid research | 2017 |
Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition
NL Meyers, M Larsson, E Vorrsjö, G Olivecrona, DM Small |
Journal of lipid research | 2017 |
Lycopene amends LPS induced oxidative stress and hypertriglyceridemia via modulating PCSK-9 expression and Apo-CIII mediated lipoprotein lipase activity
SS Alvi, IA Ansari, MK Ahmad, J Iqbal, MS Khan |
Biomedicine & Pharmacotherapy | 2017 |
Genome-Wide Association Study Reveals Four Loci for Lipid Ratios in the Korean Population and the Constitutional Subgroup
T Kim, AY Park, Y Baek, S Cha, BO Tayo |
PloS one | 2017 |
Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors
SD Prato, R Chilton |
Diabetes, obesity & metabolism | 2017 |
P-407-induced Mouse Model of Dose-controlled Hyperlipidemia and Atherosclerosis: 25 Years Later
TP Johnston, TA Korolenko, A Sahebkar |
Journal of Cardiovascular Pharmacology | 2017 |
Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial
S Ishibashi, H Arai, K Yokote, E Araki, H Suganami, S Yamashita |
Journal of Clinical Lipidology | 2017 |
Impact of bariatric surgery on apolipoprotein C-III levels and lipoprotein distribution in obese human subjects
M Maraninchi, N Padilla, S Béliard, B Berthet, JP Nogueira, J Dupont-Roussel, J Mancini, AB Corroller, N Dubois, R Grangeot, C Mattei, M Monclar, A Calabrese, C Guérin, C Desmarchelier, A Nicolay, C Xiao, P Borel, GF Lewis, R Valéro |
Journal of Clinical Lipidology | 2017 |
ApoC-III Modulates Clearance of Triglyceride-Rich Lipoproteins Through LDL Family Receptors
Philip L.S.M. Gordts, Ryan Nock, Ni-Huiping Son, Bastian Ramms, Irene Lew, Jon Gonzales, Bryan Thacker, Debapriya Basu, Richard Lee, Adam Mullick, Mark Graham, Ira J. Goldberg, rosanne Crooke, Joseph Witztum, Jeffrey D. Esko |
Journal of Clinical Investigation | 2016 |
The role of bile acids in metabolic regulation
L Vítek, M Haluzík |
Journal of Endocrinology | 2016 |
Metabolism and Modification of Apolipoprotein B-Containing Lipoproteins Involved in Dyslipidemia and Atherosclerosis
S Morita |
Biological & Pharmaceutical Bulletin | 2016 |
Loganin inhibits the inflammatory response in mouse 3T3L1 adipocytes and mouse model
Y Li, Z Li, L Shi, C Zhao, B Shen, Y Tian, H Feng |
International Immunopharmacology | 2016 |
The RNA-binding protein vigilin regulates VLDL secretion through modulation of Apob mRNA translation
MB Mobin, S Gerstberger, D Teupser, B Campana, K Charisse, MH Heim, M Manoharan, T Tuschl, M Stoffel |
Nature Communications | 2016 |
Impaired postprandial lipemic response in chronic kidney disease
JM Saland, LM Satlin, J Zalsos-Johnson, S Cremers, HN Ginsberg |
Kidney International | 2016 |
Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease
QM Anstee, D Seth, CP Day |
Gastroenterology | 2016 |
Triglyceride-rich lipoprotein metabolism in women: roles of apoC-II and apoC-III
EM Ooi, DC Chan, L Hodson, M Adiels, J Boren, F Karpe, BA Fielding, GF Watts, PH Barrett |
European Journal of Clinical Investigation | 2016 |
Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?
GM Dallinga-Thie, J Kroon, J Borén, MJ Chapman |
Current Cardiology Reports | 2016 |
Metabolic Characterization of a Rare Genetic Variation Within APOC3 and Its Lipoprotein Lipase–Independent EffectsCLINICAL PERSPECTIVE
F Drenos, GD Smith, M Ala-Korpela, J Kettunen, P Würtz, P Soininen, AJ Kangas, C Dale, DA Lawlor, TR Gaunt, JP Casas, NJ Timpson |
Circulation. Cardiovascular genetics | 2016 |
Lack of evidence for a liver or intestinal miRNA regulation involved in the hypertriglyceridemic effect of APOC3 3′UTR variant SstI
M Dancer, C Caussy, MD Filippo, P Moulin, C Marçais, S Charrière |
Atherosclerosis | 2016 |
Population Semiphysiologic Kinetic Modeling and Simulation of Plasma Triglyceride Levels After Soybean Oil–Based Intravenous Lipid Emulsion Administration in Rats
A Okada, M Hirano, M Tanioka, T Tsujimoto, H Koyama, A Nishimura, N Shibata, K Fukushima, N Sugioka |
JPEN. Journal of parenteral and enteral nutrition | 2016 |
The effect of omega-3 carboxylic acids on apolipoprotein CIII−containing lipoproteins in severe hypertriglyceridemia
AM Morton, JD Furtado, J Lee, W Amerine, MH Davidson, FM Sacks |
Journal of Clinical Lipidology | 2016 |
Apolipoprotein CIII links islet insulin resistance to β-cell failure in diabetes
K Åvall, Y Ali, IB Leibiger, B Leibiger, T Moede, M Paschen, A Dicker, E Daré, M Köhler, E Ilegems, MH Abdulreda, M Graham, RM Crooke, VS Tay, E Refai, SK Nilsson, S Jacob, L Selander, PO Berggren, L Juntti-Berggren |
Proceedings of the National Academy of Sciences | 2015 |
Update on the molecular biology of dyslipidemias
I Ramasamy |
Clinica Chimica Acta | 2015 |
Genetic background in nonalcoholic fatty liver disease: A comprehensive review
FS Macaluso |
World journal of gastroenterology : WJG | 2015 |
Apolipoprotein C-III: From Pathophysiology to Pharmacology
GD Norata, S Tsimikas, A Pirillo, AL Catapano |
Trends in Pharmacological Sciences | 2015 |
Hypertriglyceridemia in the Genomic Era: A New Paradigm
GF Lewis, C Xiao, RA Hegele |
Endocrine reviews | 2015 |
Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone
GE Ronsein, G Reyes-Soffer, Y He, M Oda, H Ginsberg, JW Heinecke |
Molecular & cellular proteomics : MCP | 2015 |
Cholesterol Metabolism in CKD
AB Reiss, I Voloshyna, JD Leon, N Miyawaki, J Mattana |
American Journal of Kidney Diseases | 2015 |
The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia:
FM Sacks |
Current Opinion in Lipidology | 2015 |
Mendel, Molecular Biology, and Apolipoprotein C-III: A Heady Combination
SB Patel |
Metabolic Syndrome and Related Disorders | 2015 |
Saroglitazar, a novel PPAR α / γ agonist with predominant PPAR α activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models
MR Jain, SR Giri, C Trivedi, B Bhoi, A Rath, G Vanage, P Vyas, R Ranvir, PR Patel |
Pharmacology Research & Perspectives | 2015 |
Tryptophan probes reveal residue-specific phospholipid interactions of apolipoprotein C-III
CM Pfefferkorn, RL Walker, Y He, JM Gruschus, JC Lee |
Biochimica et Biophysica Acta (BBA) - Biomembranes | 2015 |
Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial
RL Dunbar, SJ Nicholls, KC Maki, EM Roth, DG Orloff, D Curcio, J Johnson, D Kling, MH Davidson |
Lipids in Health and Disease | 2015 |
JCL roundtable: Apolipoproteins as causative elements in vascular disease
WV Brown, FM Sacks, AD Sniderman |
Journal of Clinical Lipidology | 2015 |
The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis
MC von Ballmoos, B Haring, FM Sacks |
Journal of Clinical Lipidology | 2015 |
Genetic variation in insulin-induced kinase signaling
IX Wang, G Ramrattan, VG Cheung |
Molecular Systems Biology | 2015 |
Liver proteomic response to hypertriglyceridemia in human-apolipoprotein C-III transgenic mice at cellular and mitochondrial compartment levels
G Ehx, S Gérin, G Mathy, F Franck, HC Oliveira, AE Vercesi, FE Sluse |
Lipids in Health and Disease | 2014 |
Tissue-specific DNA methylation profiles regulate liver-specific expression of the APOA1/C3/A4/A5 cluster and can be manipulated with demethylating agents on intestinal cells
M Guardiola, I Oliva, A Guillaumet, Á Martín-Trujillo, R Rosales, JC Vallvé, F Sabench, D Castillo, S Zaina, D Monk, J Ribalta |
Atherosclerosis | 2014 |
Comprehensive Physiology
SN Cheuvront, RW Kenefick |
Comprehensive Physiology | 2014 |
Associations between apolipoprotein CIII concentrations and microalbuminuria in type 2 diabetes
ZJ Hu, LP Ren, C Wang, B Liu, GY Song |
Experimental and therapeutic medicine | 2014 |
Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease
RS Rosenson, MH Davidson, BJ Hirsh, S Kathiresan, D Gaudet |
Journal of the American College of Cardiology | 2014 |
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
AB Jørgensen, R Frikke-Schmidt, BG Nordestgaard, A Tybjærg-Hansen |
New England Journal of Medicine | 2014 |
Phenotypes and genotypes of high density lipoprotein cholesterol in exceptional longevity
Sofiya Milman, Gil Atzmon, Jill Crandall, Nir Barzilai |
Current vascular pharmacology | 2014 |
Diabetes and Kidney Disease
EV Lerma, V Batuman |
2014 | |
Cardiac Energy Metabolism in Health and Disease
GD Lopaschuk, NS Dhalla |
2014 | |
The genetics of NAFLD
QM Anstee, CP Day |
Nature Reviews Gastroenterology & Hepatology | 2013 |
Developments in understanding bile acid metabolism
K Morimoto, H Itoh, M Watanabe |
Expert Review of Endocrinology & Metabolism | 2013 |
Relative Quantitation of Glycoisoforms of Intact Apolipoprotein C3 in Human Plasma by Liquid Chromatography–High-Resolution Mass Spectrometry
W Jian, RW Edom, D Wang, N Weng, SW Zhang |
Analytical Chemistry | 2013 |
Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association
HE Bays, PP Toth, PM Kris-Etherton, N Abate, LJ Aronne, WV Brown, JM Gonzalez-Campoy, SR Jones, R Kumar, RL Forge, VT Samuel |
Journal of Clinical Lipidology | 2013 |
Two novel mutations in apolipoprotein C3 underlie atheroprotective lipid profiles in families: Two novel mutations in apolipoprotein C3
AE Bochem, JC Capelleveen, GM Dallinga-Thie, AW Schimmel, MM Motazacker, I Tietjen, RR Singaraja, MR Hayden, JJ Kastelein, ES Stroes, GK Hovingh |
Clinical Genetics | 2013 |
Production of apolipoprotein C-III knockout rabbits using zinc finger nucleases
D Yang, J Zhang, J Xu, T Zhu, Y Fan, J Fan, YE Chen |
Journal of visualized experiments : JoVE | 2013 |
Association between the plasma proteome and plasma α-tocopherol concentrations in humans
LA da Costa, B García-Bailo, CH Borchers, A Badawi, A El-Sohemy |
The Journal of Nutritional Biochemistry | 2013 |
Apolipoprotein-defined and NMR lipoprotein subclasses in the Veterans Affairs Diabetes Trial
M Azar, TJ Lyons, P Alaupovic, JA Stoner, C Quiroga, DG Kaufman, M Lopes-Virella, RL Klein, AJ Jenkins |
Journal of Diabetes and its Complications | 2013 |
Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment
P Dongiovanni, QM Anstee, L Valenti |
Current pharmaceutical design | 2013 |
Production of Apolipoprotein C-III Knockout Rabbits using Zinc Finger Nucleases
D Yang, J Zhang, J Xu, T Zhu, Y Fan, J Fan, YE Chen |
Journal of visualized experiments : JoVE | 2013 |
Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment
P Dongiovanni, QM Anstee, L Valenti |
Current pharmaceutical design | 2013 |
Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial
G Reyes-Soffer, CI Ngai, L Lovato, W Karmally, R Ramakrishnan, S Holleran, HN Ginsberg |
Diabetes care | 2013 |
Factor II Activity is Similarly Increased in Patients With Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele
O Olivieri, N Martinelli, M Baroni, A Branchini, D Girelli, S Friso, F Pizzolo, F Bernardi |
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease | 2013 |
Omega-3 fatty acid supplementation and cardiovascular disease: Thematic Review Series: New Lipid and Lipoprotein Targets for the Treatment of Cardiometabolic Diseases
DB Jump, CM Depner, S Tripathy |
Journal of lipid research | 2012 |
Reduced kidney lipoprotein lipase and renal tubule triglyceride accumulation in cisplatin-mediated acute kidney injury
S Li, K Nagothu, G Ranganathan, SM Ali, B Shank, N Gokden, S Ayyadevara, J Megyesi, G Olivecrona, SS Chugh, S Kersten, D Portilla |
American journal of physiology. Renal physiology | 2012 |
Lipoprotein metabolism in nonalcoholic fatty liver disease
ZG Jiang, SC Robson, Z Yao |
Journal of Biomedical Research | 2012 |
New wrinkles in lipoprotein lipase biology
BS Davies, AP Beigneux, LG Fong, SG Young |
Current Opinion in Lipidology | 2012 |
Methods in Enzymology
JD Stone, AS Chervin, DH Aggen, DM Kranz |
Protein Engineering for Therapeutics Part B | 2012 |
Clinical use of genetic typing in human lipid disorders
WV Brown, J Breslow, C Ballantyne |
Journal of Clinical Lipidology | 2012 |
Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial
G Reyes-Soffer, CI Ngai, L Lovato, W Karmally, R Ramakrishnan, S Holleran, HN Ginsberg |
Diabetes care | 2012 |
Missense Mutation in APOC3 within the C-terminal Lipid Binding Domain of Human ApoC-III Results in Impaired Assembly and Secretion of Triacylglycerol-rich Very Low Density Lipoproteins
W Qin, M Sundaram, Y Wang, H Zhou, S Zhong, CC Chang, S Manhas, EF Yao, RJ Parks, PJ McFie, SJ Stone, ZG Jiang, C Wang, D Figeys, W Jia, Z Yao |
The Journal of biological chemistry | 2011 |
The Metabolic Syndrome
S Devaraj, D Siegel, I Jialal |
The Metabolic Syndrome | 2011 |
Lack of effect of apolipoprotein C3 polymorphisms on indices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans
F Sentinelli, S Romeo, C Maglio, M Incani, MA Burza, F Scano, F Coccia, E Cossu, F Leonetti, MG Baroni |
Lipids in Health and Disease | 2011 |
Effects of Prescription Omega-3-Acid Ethyl Esters on Fasting Lipid Profile in Subjects With Primary Hypercholesterolemia
KC Maki, AL Lawless, KM Kelley, MR Dicklin, VN Kaden, AL Schild, TM Rains, JW Marshall |
Journal of Cardiovascular Pharmacology | 2011 |
Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins
S Ansar, J Koska, PD Reaven |
Cardiovascular Diabetology | 2011 |
Antiretroviral treatment-induced dyslipidemia in HIV-infected patients is influenced by the APOC3-related rs10892151 polymorphism
G Aragonès, C Alonso-Villaverde, P Pardo-Reche, A Rull, R Beltrán-Debón, E Rodríguez-Gallego, L Fernández-Sender, J Camps, J Joven |
BMC Medical Genetics | 2011 |
Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia
KC Maki, HE Bays, MR Dicklin, SL Johnson, M Shabbout |
Journal of Clinical Lipidology | 2011 |
Missense Mutation in APOC3 within the C-terminal Lipid Binding Domain of Human ApoC-III Results in Impaired Assembly and Secretion of Triacylglycerol-rich Very Low Density Lipoproteins: EVIDENCE THAT ApoC-III PLAYS A MAJOR ROLE IN THE FORMATION OF LIPID PRECURSORS WITHIN THE MICROSOMAL LUMEN
W Qin, M Sundaram, Y Wang, H Zhou, S Zhong, CC Chang, S Manhas, EF Yao, RJ Parks, PJ McFie, SJ Stone, ZG Jiang, C Wang, D Figeys, W Jia, Z Yao |
The Journal of biological chemistry | 2011 |
GPIHBP1 , an endothelial cell transporter for lipoprotein lipase
SG Young, BS Davies, CV Voss, P Gin, MM Weinstein, P Tontonoz, K Reue, A Bensadoun, LG Fong, AP Beigneux |
Journal of lipid research | 2011 |
Apolipoprotein CIII Induces Monocyte Chemoattractant Protein-1 and Interleukin 6 Expression Via Toll-Like Receptor 2 Pathway in Mouse Adipocytes: Retracted
Y Abe, A Kawakami, M Osaka, S Uematsu, S Akira, K Shimokado, FM Sacks, M Yoshida |
Arteriosclerosis, thrombosis, and vascular biology | 2010 |
The Effects of Ezetimibe and/or Orlistat on Triglyceride-Rich Lipoprotein Metabolism in Obese Hypercholesterolemic Patients
ES Nakou, TD Filippatos, AP Agouridis, C Kostara, ET Bairaktari, MS Elisaf |
Lipids | 2010 |
Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia
M Sundaram, S Zhong, MB Khalil, H Zhou, ZG Jiang, Y Zhao, J Iqbal, MM Hussain, D Figeys, Y Wang, Z Yao |
Journal of lipid research | 2010 |
Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions
M Sundaram, S Zhong, MB Khalil, PH Links, Y Zhao, J Iqbal, MM Hussain, RJ Parks, Y Wang, Z Yao |
Journal of lipid research | 2010 |
Hypertriglyceridemia and delayed clearance of fat load in transgenic rabbits expressing human apolipoprotein CIII
Y Ding, Y Wang, H Zhu, J Fan, L Yu, G Liu, E Liu |
Transgenic Research | 2010 |
Apolipoprotein C-III predicts cardiovascular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation
O Olivieri, N Martinelli, D Girelli, F Pizzolo, S Friso, F Beltrame, V Lotto, L Annarumma, R Corrocher |
Journal of Thrombosis and Haemostasis | 2010 |
Apolipoprotein CIII bound to apoB-containing lipoproteins is associated with small, dense LDL independent of plasma triglyceride levels in healthy men
MJ Shin, RM Krauss |
Atherosclerosis | 2010 |
Baseline Lipoprotein Lipids and Low-Density Lipoprotein Cholesterol Response to Prescription Omega-3 Acid Ethyl Ester Added to Simvastatin Therapy
KC Maki, MR Dicklin, MH Davidson, RT Doyle, CM Ballantyne |
The American Journal of Cardiology | 2010 |
The Effect of APOC3 Promoter Polymorphisms on the Risk of Hypertriglyceridemia in Chinese Han Population With or Without Type 2 Diabetes Mellitus
J Yu, H Wang, S Yang, J Yuan, L Chen, CL Chen, DF Huang, Y Wang, SQ Ju, J Zhu |
Laboratory Medicine | 2010 |
Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia
M Sundaram, S Zhong, MB Khalil, H Zhou, ZG Jiang, Y Zhao, J Iqbal, MM Hussain, D Figeys, Y Wang, Z Yao |
Journal of lipid research | 2010 |
Metabolism of Very-Low-Density Lipoprotein and Low-Density Lipoprotein Containing Apolipoprotein C-III and Not Other Small Apolipoproteins
CO Mendivil, C Zheng, J Furtado, J Lel, FM Sacks |
Arteriosclerosis, thrombosis, and vascular biology | 2010 |
Atlas of Atherosclerosis and Metabolic Syndrome
SM Grundy |
2010 | |
High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease
EJ Schaefer |
2010 | |
Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions.
Sundaram M, Zhong S, Bou Khalil M, Links PH, Zhao Y, Iqbal J, Hussain MM, Parks RJ, Wang Y, Yao Z |
Journal of lipid research | 2010 |
Isoflavones are safe compounds for therapeutical applications – Evaluation of in vitro data
E Reiter, E Reiter, V Beck, S Medjakovic, A Jungbauer |
Gynecological Endocrinology | 2009 |
Apolipoprotein CIII Links Dyslipidemia with Atherosclerosis
A Kawakami, M Yoshida |
Journal of Atherosclerosis and Thrombosis | 2009 |
Synthesis of reconstituted high density lipoprotein (rHDL) containing apoA-I and apoC-III: the functional role of apoC-III in rHDL
KH Cho |
Molecules and Cells | 2009 |
Methods to assess impaired post-prandial metabolism and the impact for early detection of cardiovascular disease risk
JW Su, MM Nzekwu, MC Cabezas, T Redgrave, SD Proctor |
European Journal of Clinical Investigation | 2009 |
Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions
M Sundaram, S Zhong, MB Khalil, PH Links, Y Zhao, J Iqbal, MM Hussain, RJ Parks, Y Wang, Z Yao |
Journal of lipid research | 2009 |
Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III
DT Chan, GK Dogra, AB Irish, EM Ooi, PH Barrett, DC Chan, GF Watts |
Journal of lipid research | 2009 |
Endocrine and paracrine role of bile acids
V Keitel, R Kubitz, D Häussinger |
World journal of gastroenterology : WJG | 2008 |
Triglyceride-Rich Lipoprotein-Associated Apolipoprotein C-III Production Is Stimulated by Plasma Free Fatty Acids in Humans
M Pavlic, R Valéro, H Duez, C Xiao, L Szeto, BW Patterson, GF Lewis |
Arteriosclerosis, thrombosis, and vascular biology | 2008 |
Heavy marijuana users show increased serum apolipoprotein C-III levels: evidence from proteomic analyses
S Jayanthi, S Buie, S Moore, RI Herning, W Better, NM Wilson, C Contoreggi, JL Cadet |
Molecular Psychiatry | 2008 |
Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies
MA Deeg, MH Tan |
PPAR Research | 2008 |
ApoE2-associated hypertriglyceridemia is ameliorated by increased levels of apoA-V but unaffected by apoC-III deficiency
G Gerritsen, CC van der Hoogt, FG Schaap, PJ Voshol, KE Kypreos, N Maeda, AK Groen, LM Havekes, PC Rensen, KW van Dijk |
Journal of lipid research | 2008 |
Nitric oxide-releasing agent, LA419, reduces atherogenesis in apolipoprotein E-deficient mice
R Carnicer, N Guillén, JM Arbonés-Mainar, MA Navarro, MA Guzmán, C Barranquero, C Arnal, S Gascón, S Acín, M Mourelle, J Osada |
Naunyn-Schmiedeberg's Archives of Pharmacology | 2008 |
A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection
TI Pollin, CM Damcott, H Shen, SH Ott, J Shelton, RB Horenstein, W Post, JC McLenithan, LF Bielak, PA Peyser, BD Mitchell, M Miller, JR O'Connell, AR Shuldiner |
Science | 2008 |
An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?
DC Chan, MM Chen, EM Ooi, GF Watts |
International Journal of Clinical Practice | 2008 |
Distinct patterns of heparin affinity chromatography VLDL1 and VLDL2 subfractions in the different dyslipidaemias
L Duvillard, MJ Caslake, JM Petit, B Vergès, P Gambert, CJ Packard |
Atherosclerosis | 2008 |
Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome
EM Ooi, PH Barrett, DC Chan, PJ Nestel, GF Watts |
Atherosclerosis | 2008 |
Hyperlipidemia and cardiovascular disease: cardiovascular update
NA Le |
Current Opinion in Lipidology | 2008 |
Clinical presentation, laboratory values, and coronary heart disease risk in marked high-density lipoprotein–deficiency states
RD Santos, BF Asztalos, LR Martinez, MH Miname, E Polisecki, EJ Schaefer |
Journal of Clinical Lipidology | 2008 |
Alteraciones del metabolismo de las lipoproteínas. Mecanismos etiopatogénicos. Consecuencias fisiopatológicas
CR García-Andrade, LA Walther, JM Núñez-Cortés |
Medicine - Programa de Formación Médica Continuada Acreditado | 2008 |
ApoE epsilon2/epsilon3/epsilon4 polymorphism, ApoC-III/ApoE ratio and metabolic syndrome
O Olivieri, N Martinelli, A Bassi, E Trabetti, D Girelli, F Pizzolo, S Friso, PF Pignatti, R Corrocher |
Clinical and Experimental Medicine | 2008 |
ApoE2-associated hypertriglyceridemia is ameliorated by increased levels of apoA-V but unaffected by apoC-III deficiency
G Gerritsen, CC van der Hoogt, FG Schaap, PJ Voshol, KE Kypreos, N Maeda, AK Groen, LM Havekes, PC Rensen, KW van Dijk |
Journal of lipid research | 2008 |
Endocrine and paracrine role of bile acids
V Keitel, R Kubitz, D Häussinger |
World journal of gastroenterology : WJG | 2008 |
Apolipoprotein CIII polymorphism and triglyceride levels of a Japanese population living in Southern Brazil
L Parzianello, G Oliveira, JC Coelho |
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica ... [et al.] | 2008 |
Therapeutic Lipidology
MH Davidson, PP Toth, KC Maki, AM Gotto |
2008 | |
ABCA1 Promotes the de Novo Biogenesis of Apolipoprotein CIII-Containing HDL Particles in Vivo and Modulates the Severity of Apolipoprotein CIII-Induced Hypertriglyceridemia
KE Kypreos |
Biochemistry | 2008 |
Increased Plasma Apolipoprotein C-III Concentration Independently Predicts Cardiovascular Mortality: The Hoorn Study
PG Scheffer, T Teerlink, JM Dekker, G Bos, G Nijpels, M Diamant, PJ Kostense, CD Stehouwer, RJ Heine |
Clinical chemistry | 2008 |
Lipoprotein metabolism in chronic renal insufficiency
JM Saland, HN Ginsberg |
Pediatric Nephrology | 2007 |
High-density lipoprotein and transport of cholesterol and triglyceride in blood
WV Brown |
Journal of Clinical Lipidology | 2007 |
The role of hypertriglyceridemia in atherosclerosis
NA Le, MF Walter |
Current Atherosclerosis Reports | 2007 |
Associations of the apolipoprotein A1/C3/A4/A5 gene cluster with triglyceride and HDL cholesterol levels in women with type 2 diabetes
L Qi, S Liu, N Rifai, D Hunter, FB Hu |
Atherosclerosis | 2007 |
Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency
RD Santos, EJ Schaefer, BF Asztalos, E Polisecki, J Wang, RA Hegele, LR Martinez, MH Miname, CE Rochitte, PL da Luz, RC Maranhão |
Journal of lipid research | 2007 |
LXRS AND FXR: The Yin and Yang of Cholesterol and Fat Metabolism
NY Kalaany, DJ Mangelsdorf |
Annual Review of Physiology | 2006 |
Visceral Adiposity and Apolipoprotein C-III in Apolipoprotein B-Containing Lipoproteins Are Independent Predictors in Determining Atherogenic Lipid Profiles
T Han, SK Woo, S Shin, HS Kang |
Annals of Nutrition and Metabolism | 2006 |
Is apolipoprotein A5 a novel regulator of triglyceride‐rich lipoproteins?
H Jakel, M Nowak, A HelleboidChapman, J FruchartNajib, JC Fruchart |
Annals of Medicine | 2006 |
Effects of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Pioglitazone, on Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus
Kazunori Nagashima, Carlos Lopez, Daniel Donovan, Colleen Ngai, Nelson Fontanez, Andre' Bensadoun, Jamila Fruchart-Najib, Steve Holleran, Jeffrey S. Cohen, Rajasekhar Ramakrishnan, Henry N. Ginsberg |
Journal of Clinical Investigation | 2005 |
Pathophysiology of dyslipidaemia in the metabolic syndrome
GD Kolovou, KK Anagnostopoulou, DV Cokkinos |
Postgraduate medical journal | 2005 |
Antisense oligonucleotides as therapeutics for hyperlipidaemias
RM Crooke |
Expert Opinion on Biological Therapy | 2005 |
Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins
D Rimland, JL Guest, I Hernandez, C Rio, NA Le, WV Brown |
HIV Medicine | 2005 |
Variations in plasma apolipoprotein C-III levels are strong correlates of the triglyceride response to a high-monounsaturated fatty acid diet and a high-carbohydrate diet
WR Archer, S Desroches, B Lamarche, O Dériaz, N Landry, B Fontaine-Bisson, J Bergeron, P Couture, N Bergeron |
Metabolism | 2005 |
Comparison of the Relation of Triglyceride-Rich Lipoproteins and Muscular Artery Compliance in Healthy Women Versus Healthy Men
NA Le, WV Brown, WW Davis, DM Herrington, L Mosca, S Homma, B Eggleston, HJ Willens, JK Raines |
The American Journal of Cardiology | 2005 |
ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression
G Gerritsen, PC Rensen, KE Kypreos, VI Zannis, LM Havekes, KW van Dijk |
Journal of lipid research | 2005 |
Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia
M Myerson, C Ngai, J Jones, S Holleran, R Ramakrishnan, L Berglund, HN Ginsberg |
Journal of lipid research | 2005 |
Principles of Molecular Cardiology
MS Runge, C Patterson |
2005 | |
Apolipoprotein C-III, n-3 Polyunsaturated Fatty Acids, and “Insulin-Resistant” T−455C APOC3 Gene Polymorphism in Heart Disease Patients: Example of Gene-Diet Interaction
O Olivieri, N Martinelli, M Sandri, A Bassi, P Guarini, E Trabetti, F Pizzolo, D Girelli, S Friso, PF Pignatti, R Corrocher |
Clinical chemistry | 2005 |
Grape seed procyanidins improve atherosclerotic risk index and induce liver CYP7A1 and SHP expression in healthy rats
JM Bas, J Fernández-Larrea, M Blay, A Ardèvol, MJ Salvadó, L Arola, C Bladé |
The FASEB Journal | 2004 |
Pharmacotherapy of Obesity
FX Pi–Sunyer |
Pharmacotherapy of Obesity | 2004 |
The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism?
KW van Dijk, PC Rensen, PJ Voshol, LM Havekes |
Current Opinion in Lipidology | 2004 |
Apolipoprotein CIII promotes Ca2+-dependent beta cell death in type 1 diabetes
L Juntti-Berggren, E Refai, I Appelskog, M Andersson, G Imreh, N Dekki, S Uhles, L Yu, WJ Griffiths, S Zaitsev, I Leibiger, SN Yang, G Olivecrona, H Jörnvall, PO Berggren |
Proceedings of the National Academy of Sciences | 2004 |
Overexpression of apoC-III produces lesser hypertriglyceridemia in apoB-48-only gene-targeted mice than in apoB-100-only mice
K Conde-Knape, K Okada, R Ramakrishnan, NS Shachter |
Journal of lipid research | 2004 |
Apolipoprotein C-III SstI Genotypes Modulate Exercise-Induced Hypotriglyceridemia:
SK Woo, HS Kang |
Medicine and Science in Sports and Exercise | 2004 |
Effect of the Combination of Methyltestosterone and Esterified Estrogens Compared with Esterified Estrogens Alone on Apolipoprotein CIII and Other Apolipoproteins in Very Low Density, Low Density, and High Density Lipoproteins in Surgically Postmenopausal Women
SE Chiuve, LA Martin, H Campos, FM Sacks |
The Journal of clinical endocrinology and metabolism | 2004 |
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression
T Claudel, Y Inoue, O Barbier, D Duran-Sandoval, V Kosykh, J Fruchart, JC Fruchart, FJ Gonzalez, B Staels |
Gastroenterology | 2003 |
Ragaglitazar: a novel PPARα& PPARγagonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models
R Chakrabarti, RK Vikramadithyan, P Misra, J Hiriyan, S Raichur, RK Damarla, C Gershome, J Suresh, R Rajagopalan |
British Journal of Pharmacology | 2003 |
Influence of polymorphism (RFLP-sstI) at the apolipoprotein C-III gene locus on the lipoprotein metabolism and insulin resistance in essential hypertensive patients. Interaction between gender and genetic polymorphism
A Espino-Montoro, M Barrios-Artillo, JM López-Chozas, A Cayuela, P Stiefel, J Villar |
Nutrition, Metabolism and Cardiovascular Diseases | 2003 |
Indices related to apo CII and CIII serum concentrations and coronary heart disease: a case–control study
Y Gerber, U Goldbourt, S Segev, D Harats |
Preventive Medicine | 2003 |
Hypertriglyceridemia but not diabetes status is associated with VLDL containing apolipoprotein CIII in patients with coronary heart disease
SJ Lee, LA Moye, H Campos, GH Williams, FM Sacks |
Atherosclerosis | 2003 |
Apolipoprotein CIII deficiency prevents the development of hypertriglyceridemia in streptozotocin-induced diabetic mice
T Takahashi, T Hirano, K Okada, M Adachi |
Metabolism | 2003 |
Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus
SJ Lee, FM Sacks |
The American Journal of Cardiology | 2003 |
Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients
JD Morrisett, G Abdel-Fattah, BD Kahan |
Transplantation Proceedings | 2003 |
Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease
O Olivieri, A Bassi, C Stranieri, E Trabetti, N Martinelli, F Pizzolo, D Girelli, S Friso, PF Pignatti, R Corrocher |
Journal of lipid research | 2003 |
Effect of apoC-III gene polymorphisms on the lipoprotein-lipid profile of viscerally obese men
C Couillard, MC Vohl, JC Engert, I Lemieux, A Houde, N Alméras, D Prud'homme, A Nadeau, JP Després, J Bergeron |
Journal of lipid research | 2003 |
Effects of plasma apolipoproteins on lipoprotein lipase-mediated lipolysis of small and large lipid emulsions
M Yamamoto, S Morita, M Kumon, M Kawabe, K Nishitsuji, H Saito, A Vertut-Doı̈, M Nakano, T Handa |
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids | 2003 |
The apolipoprotein CIII T2854G variants are associated with postprandial triacylglycerol concentrations in normolipidemic Korean men
SK Woo, HS Kang |
Journal of Human Genetics | 2003 |
Atlas of Atherosclerosis
PW Wilson |
2003 | |
Apolipoprotein C3 SstI polymorphism and triglyceride levels in Asian Indians
S Chhabra, R Narang, LR Krishnan, S Vasisht, DP Agarwal, LM Srivastava, SC Manchanda, N Das |
BMC genetics | 2002 |
Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids
J Graaf, MJ Veerkamp, AF Stalenhoef |
Journal of the Royal Society of Medicine | 2002 |
Lipoprotein lipase: genetics, lipid uptake, and regulation
M Merkel |
The Journal of Lipid Research | 2002 |
Orphan Nuclear Hormone Receptor Rev-erbα Regulates the Human Apolipoprotein CIII Promoter
H Coste, JC Rodrı́guez |
The Journal of biological chemistry | 2002 |
Metabolic origins and clinical significance of LDL heterogeneity
KK Berneis, RM Krauss |
Journal of lipid research | 2002 |
ApoC-III gene polymorphisms and risk of coronary artery disease
O Olivieri, C Stranieri, A Bassi, B Zaia, D Girelli, F Pizzolo, E Trabetti, S Cheng, MA Grow, PF Pignatti, R Corrocher |
Journal of lipid research | 2002 |
New Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism
HN Ginsberg |
Circulation | 2002 |
Markers of Triglyceride-rich Lipoprotein Remnant Metabolism in Visceral Obesity
DC Chan, GF Watts, PH Barrett, JC Mamo, TG Redgrave |
Clinical chemistry | 2002 |
Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients
JD Morrisett, G Abdel-Fattah, R Hoogeveen, E Mitchell, CM Ballantyne, HJ Pownall, AR Opekun, JS Jaffe, S Oppermann, BD Kahan |
Journal of lipid research | 2002 |
Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism
NS Shachter |
Current Opinion in Lipidology | 2001 |
Differential metabolism of human VLDL according to content of ApoE and ApoC-III
K Tomiyasu, BW Walsh, K Ikewaki, H Judge, FM Sacks |
Arteriosclerosis, thrombosis, and vascular biology | 2001 |
Genetic influences on lipid metabolism trait variability within the Stanislas Cohort
C Pallaud, R Gueguen, C Sass, M Grow, S Cheng, G Siest, S Visvikis |
Journal of lipid research | 2001 |
Dietary fat saturation distinctly affects apolipoprotein gene expression and high density lipoprotein size distribution in two strains of Golden Syrian hamsters
D Smith, YS Ahn, J Pedro-Botet, J Osada, P Mata, EJ Schaefer, JM Ordovas |
Nutrition Research | 2001 |
Apoprotein C-III deficiency markedly stimulates triglyceride secretion in vivo: comparison with apoprotein E
T Hirano, T Takahashi, S Saito, H Tajima, T Ebara, M Adachi |
American journal of physiology. Endocrinology and metabolism | 2001 |
Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia
H Campos, D Perlov, C Khoo, FM Sacks |
Journal of lipid research | 2001 |
Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice
MC Jong, PC Rensen, VE Dahlmans, H van der Boom, TJ van Berkel, LM Havekes |
Journal of lipid research | 2001 |
Postprandial concentrations and distribution of apo C-III in type 2 diabetic patients. Effect of bezafibrate treatment
N Attia, V Durlach, M Cambilleau, D Roche, A Girard-Globa |
Atherosclerosis | 2000 |
Alteration in Expression Profiles of a Series of Diabetes-Related Genes in db/db Mice Following Treatment With Thiazolidinediones
A Suzuki, T Yasuno, H Kojo, J Hirosumi, S Mutoh, Y Notsu |
The Japanese Journal of Pharmacology | 2000 |
Transport des lipidesFonction des apolipoprotéines
B Perret, R Milne, X Collet |
Annales de l'Institut Pasteur/Actualités | 2000 |
Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: Effect of triglyceride reductions with atorvastatin
NA Le, W Innis-Whitehouse, X Li, R Bakker-Arkema, D Black, WV Brown |
Metabolism | 2000 |
Le rôle de ses activateurs dans la régulation de l'expression des gènes impliqués dans le métabolisme des lipoprotéines, l'inflammation vasculaire et l'athérosclérose
P Duriez, B Staels, JC Fruchart |
Annales de l'Institut Pasteur/Actualit�s | 2000 |
Lipoprotein Metabolism and Atherogenesis
T Kita, M Yokode |
2000 | |
Characterization of Recombinant Wild Type and Site-Directed Mutations of Apolipoprotein C-III: Lipid Binding, Displacement of ApoE, and Inhibition of Lipoprotein Lipase
H Liu, PJ Talmud, L Lins, R Brasseur, G Olivecrona, F Peelman, J Vandekerckhove, M Rosseneu, C Labeur |
Biochemistry | 2000 |
Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions
CJ Packard, T Demant, JP Stewart, D Bedford, MJ Caslake, G Schwertfeger, A Bedynek, J Shepherd, D Seidel |
Journal of lipid research | 2000 |
Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr
H Liu, C Labeur, CF Xu, R Ferrell, L Lins, R Brasseur, M Rosseneu, KM Weiss, SE Humphries, PJ Talmud |
Journal of lipid research | 2000 |
Apolipoprotein C-III can specifically bind to hepatic plasma membranes
D Z Fang, B W Liu |
Molecular and Cellular Biochemistry | 2000 |
Apolipoprotein E polymorphism in men and women from a Spanish population: allele frequencies and influence on plasma lipids and apolipoproteins
D Gómez-Coronado, JJ Álvarez, A Entrala, JM Olmos, E Herrera, MÁ Lasunción |
Atherosclerosis | 1999 |
Peroxisome proliterator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis
JC Fruchart, P Duriez, B Staels |
Current Opinion in Lipidology | 1999 |
Fibrates, dyslipoproteinaemia and cardiovascular disease
GF Watts, SB Dimmitt |
Current Opinion in Lipidology | 1999 |
Interrelationships between postprandial lipoprotein B:CIII particle changes and high-density lipoprotein subpopulation profiles in mixed hyperlipoproteinemia
Y Saïdi, D Sich, A Camproux, M Egloff, MC Federspiel, V Gautier, A Raisonnier, G Turpin, I Beucler |
Metabolism | 1999 |
Hypertriglyceridemia, insulin resistance, and the metabolic syndrome
SM Grundy |
The American Journal of Cardiology | 1999 |
Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease
HB Brewer |
The American Journal of Cardiology | 1999 |
3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase
K Schoonjans, J Peinado-Onsurbe, JC Fruchart, A Tailleux, C Fiévet, J Auwerx |
FEBS Letters | 1999 |
Apolipoprotein C-III displacement of apolipoprotein E from VLDL: effect of particle size
ED Breyer, NA Le, X Li, D Martinson, WV Brown |
Journal of lipid research | 1999 |
Mitogen-activated Protein Kinase Regulates Transcription of the ApoCIII Gene: INVOLVEMENT OF THE ORPHAN NUCLEAR RECEPTOR HNF4
S Reddy, W Yang, DG Taylor, X Shen, D Oxender, G Kust, T Leff |
The Journal of biological chemistry | 1999 |
Detection, Quantification, and Characterization of Potentially Atherogenic Triglyceride-Rich Remnant Lipoproteins
JS Cohn, C Marcoux, J Davignon |
Arteriosclerosis, thrombosis, and vascular biology | 1999 |
Contemporary Concepts in Cardiology
R Gorlin, G Dangas, PK Toutouzas, MM Konstadoulakis |
1999 | |
Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content
C Khoo, H Campos, H Judge, FM Sacks |
Journal of lipid research | 1999 |
Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids
N Vu-Dac, P Gervois, IP Torra, JC Fruchart, V Kosykh, T Kooistra, HM Princen, J Dallongeville, B Staels |
Journal of Clinical Investigation | 1998 |
Defects of lipoprotein metabolism in familial combined hyperlipidaemia
J Graaf, AF Stalenhoef |
Current Opinion in Lipidology | 1998 |
LIPOPROTEIN PHYSIOLOGY
HN Ginsberg |
Endocrinology & Metabolism Clinics of North America | 1998 |
A peptide from hog plasma that inhibits human cholesteryl ester transfer protein
K Cho |
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism | 1998 |
PPAR$gamma; activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes
G Martin, K Schoonjans, B Staels, J Auwerx |
Atherosclerosis | 1998 |
ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice
E Voyiaziakis, IJ Goldberg, AS Plump, EM Rubin, JL Breslow, LS Huang |
Journal of lipid research | 1998 |
Transient triglyceridemia in healthy normolipidemic men increases cellular processing of large very low density lipoproteins by fibroblasts in vitro
J Björkegren, F Karpe, S Vitols, P Tornvall, A Hamsten |
Journal of lipid research | 1998 |
Differences in apolipoprotein and lipid composition between human chylomicron remnants and very low density lipoproteins isolated from fasting and postprandial plasma
J Björkegren, F Karpe, RW Milne, A Hamsten |
Journal of lipid research | 1998 |
Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E
T Ebara, R Ramakrishnan, G Steiner, NS Shachter |
Journal of Clinical Investigation | 1997 |
Variation at the lipoprotein lipase and apolipoprotein AI-CIII gene loci are associated with fasting lipid and lipoprotein traits in a population sample from Iceland: Interaction between genotype, gender, and smoking status
RE Peacock, A Temple, V Gudnason, M Rosseneu, SE Humphries |
Genetic Epidemiology | 1997 |
The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs)
B Staels, K Schoonjans, JC Fruchart, J Auwerx |
Biochimie | 1997 |
Inhibitory Effects of Specific Apolipoprotein C-III Isoforms on the Binding of Triglyceride-rich Lipoproteins to the Lipolysis-stimulated Receptor
CJ Mann, AA Troussard, FT Yen, N Hannouche, J Najib, JC Fruchart, V Lotteau, P André, BE Bihain |
The Journal of biological chemistry | 1997 |
Lipoprotein Heterogeneity and Apolipoprotein B Metabolism
CJ Packard, J Shepherd |
Arteriosclerosis, thrombosis, and vascular biology | 1997 |
Alterations of VLDL composition during alimentary lipemia
J Björkegren, A Hamsten, RW Milne, F Karpe |
Journal of lipid research | 1997 |
A variation in the apolipoprotein C-III gene is associated with an increased number of circulating VLDL and IDL particles in familial combined hyperlipidemia
J Ribalta, AE Ville, JC Vallvé, S Humphries, PR Turner, L Masana |
Journal of lipid research | 1997 |
Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl
NS Shachter, T Ebara, R Ramakrishnan, G Steiner, JL Breslow, HN Ginsberg, JD Smith |
Journal of Clinical Investigation | 1996 |
Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR
J Auwerx, K Schoonjans, JC Fruchart, B Staels |
Atherosclerosis | 1996 |
In vitro lipolysis of human VLDL: Effect of different VLDL compositions in normolipidemia, familial combined hyperlipidemia and familial hypertriglyceridemia
HH van Barlingen, LA Kock, FH de Man, DW Erkelens, TW de Bruin |
Atherosclerosis | 1996 |
Apo B-containing lipoprotein particles in poorly controlled insulin-dependent diabetes
B Igau, S Lestavel, V Clavey, C Slomianny, P Drouin, R Bresson, JC Fruchart, P Duriez, C Fiévet |
Atherosclerosis | 1996 |
Hypolipidemic Effect of Peroxisome Proliferators
R Hertz, J Bishara-Shieban, J Bar-Tana |
Annals of the New York Academy of Sciences | 1996 |
Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis
IJ Goldberg |
Journal of lipid research | 1996 |
The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation
K Schoonjans, B Staels, J Auwerx |
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism | 1996 |
Regulation of Triglyceride Metabolism by PPARs : Fibrates and Thiazolidinediones have Distinct Effects
J Auwerx, K Schoonjans, JC Fruchart, B Staels |
Journal of Atherosclerosis and Thrombosis | 1996 |
Drugs Affecting Lipid Metabolism
AM Gotto, R Paoletti, LC Smith, AL Catapano, AS Jackson |
1996 | |
Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression
K Schoonjans, B Staels, J Auwerx |
Journal of lipid research | 1996 |
Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates
B Staels, N Vu-Dac, VA Kosykh, R Saladin, JC Fruchart, J Dallongeville, J Auwerx |
Journal of Clinical Investigation | 1995 |
Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia
WW Li, MM Dammerman, JD Smith, S Metzger, JL Breslow, T Leff |
Journal of Clinical Investigation | 1995 |
Lipids and atherosclerosis
MJ Halpern |
Molecular Aspects of Medicine | 1995 |
Characterization of Apolipoproteins B-100, AI and C from Plasma Lipoprotein in the Goose, Anser anser. Evidence for a Genetic Polymorphism in ApoC-like Apolipoproteins
D Hermier, N Sellier, D Rousselot-Pailley, P Forgez |
European Journal of Biochemistry | 1995 |
Mode of Action of Peroxisome Proliferators as Hypolipidemic Drugs.: SUPPRESSION OF APOLIPOPROTEIN C-III
R Hertz, J Bishara-Shieban, J Bar-Tana |
The Journal of biological chemistry | 1995 |
Elevated Concentrations of Plasma Lipids and Apolipoproteins B, C-III, and E Are Associated With the Progression of Coronary Artery Disease in Familial Hypercholesterolemic Swine
J Hasler-Rapacz, MF Prescott, JV Linden-Reed, JM Rapacz, Z Hu, J Rapacz |
Arteriosclerosis, thrombosis, and vascular biology | 1995 |
Modulation of Lipoprotein B Binding to the LDL Receptor by Exogenous Lipids and Apolipoproteins CI, CII, CIII, and E
V Clavey, S Lestavel-Delattre, C Copin, JM Bard, JC Fruchart |
Arteriosclerosis, thrombosis, and vascular biology | 1995 |
Association between genetic variation at the APO AI-CIII-AIV gene cluster and familial combined hyperlipidaemia
CF Xu, P Talmud, H Schuster, R Houlston, G Miller, S Humphries |
Clinical Genetics | 1994 |
Blood pressure, coronary artery disease, and glycaemic control in type 2 diabetes mellitus: relation to apolipoprotein-CIII gene polymorphism
S Tas, NA Abdella |
The Lancet | 1994 |
The effect of beta,beta'-tetramethylhexadecanedioic acid (MEDICA 16) on plasma very-low-density lipoprotein metabolism in rats: role of apolipoprotein C-III
B Frenkel, J Bishara-Shieban, J Bar-Tana |
Biochemical Journal | 1994 |
Lipids and apolipoproteins in growth hormone-deficient children during treatment
GB Schaefer, NG Greger, JD Fesmire, PR Blackett, DP Wilson, JP Frindik |
Metabolism | 1994 |
Lipoprotein metabolism and its relationship to atherosclerosis
HN Ginsberg |
Medical Clinics of North America | 1994 |
Associations of allelic differences at the A-I/C-III/A-IV gene cluster with carotid artery intima-media thickness and plasma lipid transport in hypercholesterolemic-hypertriglyceridemic humans
W Patsch, AR Sharrett, IY Chen, YC Lin-Lee, SA Brown, AM Gotto, E Boerwinkle |
Arteriosclerosis Thrombosis and Vascular Biology | 1994 |
Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E
HV de Silva, SJ Lauer, J Wang, WS Simonet, KH Weisgraber, RW Mahley, JM Taylor |
The Journal of biological chemistry | 1994 |
Identification of functional domains in the plasma apolipoproteins by analysis of inter-species sequence variability
RB Weinberg |
Journal of lipid research | 1994 |
Electrophoretic screening for genetic variation in apolipoprotein C-III: identification of a novel apoC-III variant, apoC-III(Asp45–>Asn), in a Turkish patient
S Lüttmann, A von Eckardstein, W Wei, H Funke, E Köhler, RW Mahley, G Assmann |
Journal of lipid research | 1994 |
Kinetics of lipolysis of very low density lipoproteins by lipoprotein lipase. Importance of particle number and noncompetitive inhibition by particles with low triglyceride content
PW Connelly, GF Maguire, C Vezina, RA Hegele, A Kuksis |
The Journal of biological chemistry | 1994 |
Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia
N Maeda, H Li, D Lee, P Oliver, SH Quarfordt, J Osada |
The Journal of biological chemistry | 1994 |
Lipoprotein Metabolism: An Overview
J Shepherd |
Drugs | 1994 |
Metabolism of triglyceride-rich lipoproteins during alimentary lipemia
F Karpe, G Steiner, T Olivecrona, LA Carlson, A Hamsten |
Journal of Clinical Investigation | 1993 |
Genetic markers in the apo AI-CIII-AIV gene cluster for combined hyperlipidemia, hypertriglyceridemia, and predisposition to atherosclerosis
A Tybjærg-Hansen, BG Nordestgaard, LU Gerdes, O Færgeman, SE Humphries |
Atherosclerosis | 1993 |
Nucleotide sequences of the Macaca fascicularis apolipoprotein C-III and A-IV genes
J Osada, M Pocoví, RJ Nicolosi, EJ Schaefer, JM Ordovás |
Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression | 1993 |
Quantification of Human Plasma Apolipoproteins C-I, C-II, and C-III by Radioimmunoassays
ND Bren, A Rastogi, BA Kottke |
Mayo Clinic Proceedings | 1993 |
Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice
C Glass, RC Pittman, DB Weinstein, D Steinberg |
Arteriosclerosis Thrombosis and Vascular Biology | 1993 |
Modulation of the expression of human LDL-Apo B-100 epitopes by lipids and apolipoproteins
P Harduin, A Tailleux, JC Fruchart, C Fievet |
Arteriosclerosis Thrombosis and Vascular Biology | 1993 |
HDLs and alimentary lipemia. Studies in men with previous myocardial infarction at a young age
F Karpe, JM Bard, G Steiner, LA Carlson, JC Fruchart, A Hamsten |
Arteriosclerosis Thrombosis and Vascular Biology | 1993 |
Impaired chylomicron remnant clearance in familial combined hyperlipidemia
MC Cabezas, TW de Bruin, H Jansen, LA Kock, W Kortlandt, DW Erkelens |
Arteriosclerosis Thrombosis and Vascular Biology | 1993 |
Role of thyroid hormone in the expression of apolipoprotein A-IV and C-III genes in rat liver
YC Lin-Lee, W Strobl, S Soyal, M Radosavljevic, M Song, AM Gotto, W Patsch |
Journal of lipid research | 1993 |
Abnormal activation of lipoprotein lipase by non-equilibrating apoC-II: further evidence for the presence of non-equilibrating pools of apolipoproteins C-II and C-III in plasma lipoproteins
L Tornoci, CA Scheraldi, X Li, H Ide, IJ Goldberg, NA Le |
Journal of lipid research | 1993 |
Effect of sucrose diet on expression of apolipoprotein genes A-I, C-III and A-IV in rat liver
M Radosavljevic, Y Lin-Lee, SM Soyal, W Strobl, C Seelos, AM Gotto, W Patsch |
Atherosclerosis | 1992 |
Antagonism between apolipoprotein AI regulatory protein 1, Ear3/COUP-TF, and hepatocyte nuclear factor 4 modulates apolipoprotein CIII gene expression in liver and intestinal cells
M Mietus-Snyder, FM Sladek, GS Ginsburg, CF Kuo, JA Ladias, JE Darnell, SK Karathanasis |
Molecular and cellular biology | 1992 |
Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia
A Eckardstein, H Holz, M Sandkamp, W Weng, H Funke, G Assmann |
Journal of Clinical Investigation | 1991 |
Clinical chemistry
DJ Anderson, FV Lente, FS Apple, SC Kazmierczak, JA Lott, MK Gupta, N McBride, WE Katzin, RE Scott, al. |
Analytical Chemistry | 1991 |
Interaction of LpB, LpB:E, LpB:C-III, and LpB:C-III:E lipoproteins with the low density lipoprotein receptor of HeLa cells
G Agnani, JM Bard, L Candelier, S Delattre, JC Fruchart, V Clavey |
Arteriosclerosis Thrombosis and Vascular Biology | 1991 |
Familial combined hyperlipidaemia linked to the apolipoprotein AI–CIII–AIV gene cluster on chromosome 11q23q–q24
AP Wojciechowski, M Farrall, P Cullen, TM Wilson, JD Bayliss, B Farren, BA Griffn, MJ Caslake, CJ Packard, J Shepherd, R Thakker, J Scott |
Nature | 1991 |
Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E
L Chivot, F Mainard, E Bigot, JM Bard, JL Auget, Y Madec, JC Fruchart |
Atherosclerosis | 1990 |
The 3′-Flanking Region Shared by the Human Apolipoprotein AI and CIII Gene Regulates Gene Expression in Cooperation with 5′-Flanking Elements
A HAASE, W STOFFEL |
Biological Chemistry Hoppe-Seyler | 1990 |
Lipid and apoprotein modifications in body builders during and after self-administration of anabolic steroids
G Baldo-Enzi, F Giada, G Zuliani, L Baroni, E Vitale, G Enzi, P Magnanini, R Fellin |
Metabolism | 1990 |
Nonuniform radiolabeling of VLDL apolipoprotein B: implications for the analysis of studies of the kinetics of the metabolism of lipoproteins containing apolipoprotein B
R Ramakrishnan, Y Arad, S Wong, HN Ginsberg |
Journal of lipid research | 1990 |
9 Hypertriglyceridaemia, triglyceride-rich lipoproteins and coronary heart disease
A Hamsten |
Baillière's Clinical Endocrinology and Metabolism | 1990 |
Lipoprotein Physiology and Its Relationship to Atherogenesis
HN Ginsberg |
Endocrinology and metabolism clinics of North America | 1990 |
Role of triglyceride-rich lipoproteins in progression of atherosclerosis
RJ Havel |
Circulation | 1990 |
Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors
DH Blankenhorn, P Alaupovic, E Wickham, HP Chin, SP Azen |
Circulation | 1990 |
Hypercholesterolemia, Hypocholesterolemia, Hypertriglyceridemia, in Vivo Kinetics
CL Malmendier, P Alaupovic, HB Brewer |
1990 | |
Hypertriglyceridemia as a Result of Human apo CII Gene Expression in Transgenic Mice
Y Ito, N Azrolan, A O'Connell, A Walsh, JL Breslow |
Science | 1990 |
Changes in lipoproteins induced by the remnant kidney tissue or binephrectomy in chronic uremic patients treated by hemodialysis
D Robert, R Jeanmonod, H Favre, JC Fruchart, E Sturzenegger, W Riesen |
Metabolism | 1989 |
Lipoprotein lipase in rat heart—II. influence of apolipoproteins and nutritional factors on tri- di- and monoacylglycerol lipase activities in post-heparin effluents
A Verine, M Benkirane, JM Meignen, J Boyer |
Comparative Biochemistry and Physiology Part B: Comparative Biochemistry | 1989 |
Chenodeoxycholic acid normalizes elevated lipoprotein secretion and catabolism in cerebrotendinous xanthomatosis
GS Tint, H Ginsberg, G Salen, NA Le, S Shefer |
Journal of lipid research | 1989 |
Very low density lipoprotein apolipoprotein B metabolism in humans
T Demant, J Shepherd, CJ Packard |
Klinische Wochenschrift | 1988 |
Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins
NA Le, JC Gibson, HN Ginsberg |
Journal of lipid research | 1988 |
The hypochylomicronemic effect of beta,beta'-methyl-substituted hexadecanedioic acid (MEDICA 16) is mediated by a decrease in apolipoprotein C-III
B Frenkel, N Mayorek, R Hertz, J Bar-Tana |
The Journal of biological chemistry | 1988 |
Hypolipidemic effect of beta, beta'-methyl-substituted hexadecanedioic acid (MEDICA 16) in normal and nephrotic rats
J Bar-Tana, G Rose-Kahn, B Frenkel, Z Shafer, M Fainaru |
Journal of lipid research | 1988 |
Activation of lipoprotein lipase by apolipoprotein C-II is modulated by the COOH terminal region of apolipoprotein C-III
AL Catapano |
Chemistry and Physics of Lipids | 1987 |
1 Lipid transport through the plasma: the metabolic basis of hyperlipidaemia
J Shepherd, CJ Packard |
Baillière's Clinical Endocrinology and Metabolism | 1987 |
7 Enzymes involved in triglyceride hydrolysis
MR Taskinen, T Kuusi |
Baillière's Clinical Endocrinology and Metabolism | 1987 |
Studies on the mechanism of hypertriglyceridemia in Tangier disease. Determination of plasma lipolytic activities, k1 values and apolipoprotein composition of the major lipoprotein density classes
CS Wang, P Alaupovic, RE Gregg, HB Brewer |
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism | 1987 |
Structure and expression of dog apolipoprotein C-II and C-III mRNAs. Implications for the evolution and functional constraints of apolipoprotein structure
S Datta, WH Li, I Ghosh, CC Luo, L Chan |
The Journal of biological chemistry | 1987 |